Drive along North Torrey Pines Road in La Jolla and the landscape does not look like a typical industrial district. Low buildings of glass and concrete sit on a coastal mesa, with research institutes whose names are known to scientists around the world, and across the street are laboratories leased by young companies. San Diego’s life sciences cluster, sometimes nicknamed “Biotech Beach,” is one of the largest concentrations of biotechnology, pharmaceutical and medical device activity in the country. Understanding how it formed and how it works helps explain a good part of the regional economy.
What counts as the life sciences?
The term covers several related industries. Biotechnology companies use biological systems to develop therapies, diagnostics and tools. Pharmaceutical companies develop and manufacture drugs. Medical device firms make equipment from implants to diagnostic machines. Research and testing services, including contract research organizations, support the work, and a broader ecosystem of lawyers, investors, lab suppliers and recruiters grows up around it.
Because these categories overlap, published counts of companies and jobs differ depending on definitions and methods. Industry reports describe tens of thousands of jobs in the San Diego region and a company count in the low thousands, depending on what is included, and readers should look at the method behind a figure before comparing numbers from different sources.
How did it form?
The cluster began with research institutions. Beginning in the 1960s, several major institutes and a new University of California campus settled on the Torrey Pines Mesa. The Salk Institute for Biological Studies, founded by Jonas Salk, opened there in the early 1960s. The Scripps Research Institute, UC San Diego, which was established in the same period, and the Sanford Burnham Prebys Medical Discovery Institute, along with the La Jolla Institute for Immunology, joined to create a dense neighborhood of laboratories. The region’s research strength drew scientists, and their discoveries led to companies.
A common pattern is that a scientist or a team leaves a lab or university with a technology, raises money and starts a company in nearby space. Some of those firms grow, others are acquired by larger companies, and many experienced employees go on to found new ones, which reinforces the cluster. Over the decades, the region has produced companies that developed well-known drugs and diagnostics, and large pharmaceutical firms have opened research sites here to be close to the talent and startups.
What makes a cluster work?
Several ingredients reinforce each other.
- Research institutions. Universities and nonprofit institutes generate discoveries and train scientists, covered in part in the guide to the region’s higher education systems.
- Talent. A large pool of scientists, technicians and engineers can move among employers without leaving the region, which makes it easier for companies to hire.
- Capital. Venture capital firms and investors who understand the field are located in or visit the region. Funding is cyclical, and the availability of money for early-stage companies has risen and fallen with markets.
- Lab space and real estate. Specialized buildings with ventilation, power and equipment are essential, and developers have built extensively to meet the demand. Shared laboratory facilities allow startups to avoid the cost of building their own.
- Networking and trade groups. Organizations such as Biocom California, an industry association, bring companies together, advocate on policy and publish economic reports.
- Support services. Patent attorneys, regulatory consultants, clinical research firms and manufacturers form a supporting network.
The effect is that being close to others in the field is an advantage, which is why firms cluster even though the real estate is expensive.
How does a drug get from the lab to patients?
The path is long and risky, which shapes the way companies behave. A promising molecule must be tested in the laboratory and in animals, then enter clinical trials in people, which proceed in phases and are overseen by the federal Food and Drug Administration. Most candidates fail at some stage, and the process takes years and costs very large sums. Small companies often rely on investors to fund them through that period and may partner with or sell to larger firms that can run late-stage trials and market products.
That structure explains why funding cycles matter so much. When investors are cautious, startups may cut staff or merge, and when markets are strong, new companies form and hire. San Diego’s life sciences employment has risen and fallen with those cycles, and industry reports in recent years have described job losses tied to higher interest rates and reduced venture funding, even while the region’s research base remains strong.
What is the connection to the rest of the economy?
The life sciences are one of the region’s signature industries, along with defense, tourism and cross-border trade, as discussed in the regional economy guide. The jobs tend to pay well, though they require advanced training, and they support other employers through spending and the demand for services. The industry also shapes the real estate market on the mesa and in areas such as Sorrento Valley and Carlsbad, where biotech firms and manufacturers have expanded.
Technology and life sciences increasingly overlap, with data science, artificial intelligence and software playing larger roles in drug discovery and diagnostics. That makes questions about handling personal health data more important, which links to the privacy rules explained in your privacy rights under the CCPA and CPRA.
What are the pressures?
The cluster faces several challenges. Housing costs make it harder to recruit and retain workers. Competition from other biotech hubs, such as Boston and the San Francisco Bay Area, is intense. Funding volatility creates uncertainty. Federal policy affects research funding, drug approval and trade. And the supply of lab space can swing between shortage and glut. Local governments and business groups work to address these issues through planning, workforce training and advocacy, and regional planning decisions about housing and transportation, such as those described in what SANDAG does, affect whether workers can live near their jobs.
What do the jobs look like?
The industry employs far more than bench scientists. Roles include process engineers, quality and regulatory specialists, clinical research coordinators, data analysts, lab technicians, manufacturing operators and sales and finance staff. Community college programs in biotechnology and manufacturing train technicians, universities supply scientists and engineers, and many companies run internships. Because career paths cross employers, workers often move among startups and larger firms, building skills along the way. Residents curious about entry points can start with local college biotechnology programs and the job boards that industry associations maintain.
How can someone learn more?
Biocom California publishes regular economic impact reports, and the San Diego Regional Economic Development Corporation tracks the sector’s role in the economy. The research institutes host public lectures and tours, and UC San Diego hosts events open to the community. Readers who want to follow the industry can look at announcements of clinical trial results, funding rounds and new facilities, always keeping in mind that early-stage biotech is a field where promising news often precedes long delays or setbacks.
The cluster is a reminder that economic strength can grow from the ground up, around institutions, talent and a willingness of people to start companies. It is also a reminder that such strength depends on continuing investment in all of those parts.
Sources: Biocom California; San Diego Regional Economic Development Corporation; U.S. Food and Drug Administration; Salk Institute for Biological Studies
